Program
Gabapentin
Also written as “gabapentin”, “gabapentin 600 mg” and “Gabapentin Extended Release tablets”.
Its studies are mostly in Sleep Initiation and Maintenance Disorders · Hot Flashes · Diabetic Neuropathies · Epilepsies, Partial · Neuralgia, Postherpetic, led by 8 companies.
Drug pageGabapentin: every studyMany companies study it; this page follows only the 44 they lead. All 334 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatrisits history only | 201 open or running | phase 4since Sep 28, 2007 | Sep 8, 2005 | Jan 31, 2027phase 4 · NCT07813026 |
| Depomedits history only | 80 open or running | phase 4since Jun 5, 2017 | Jun 8, 2006 | none ahead |
| Teva Pharmaceutical Industriesits history only | 60 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| Sun Pharmaceutical Industries | 40 open or running | no phasesince Oct 22, 2008 | Oct 22, 2008 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 1since Sep 29, 2011 | Sep 29, 2011 | none ahead |
| Pharmaceutical Research Management srlits history only | 20 open or running | phase 3since Mar 18, 2016 | Mar 18, 2016 | none ahead |
| Nang Kuang Pharmaceuticalits history only | 10 open or running | phase 4since Feb 24, 2014 | Feb 24, 2014 | none ahead |
| Pfizerits history only | 10 open or running | phase 1since May 5, 2010 | May 5, 2010 | none ahead |
Also a collaborator on its studies: Chiltern International and Boehringer Ingelheim.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sun Pharmaceutical Industries only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 22, 2008First studies: 4 no phase studies in HealthyFirst studyNCT00778765, NCT00778401, NCT00778271 and 1 more
TargetBeta
“Voltage-gated calcium channel modulator”ChEMBL 37, by rule
Other programs on the same 26 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pregabalinrule | Viatris | phase 4 | 149 |
Studies
All 4 Sun Pharmaceutical Industries leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00778765Healthy · Canada | – | Completed | Oct 2002 | 24 |
| NCT00778401Healthy · United States | – | Completed | Oct 2002 | 28 |
| NCT00778271Healthy · Canada | – | Completed | Oct 2002 | 26 |
| NCT00778232Healthy · United States | – | Completed | Nov 2002 | 22 |
How it is read
Names in the registry
- “Gabapentin”, 27 entries
- “gabapentin”, 5 entries
- “gabapentin 600 mg”, 3 entries
- “Gabapentin Extended Release tablets”, 3 entries
- “Gabapentin 800 mg tablets, single dose (1 tablet)”, 3 entries
Conditions, from the studies’ own filings
- Sleep Initiation and Maintenance Disorders, 10 studies
- Hot Flashes, 4 studies
- Diabetic Neuropathies, 3 studies
- Epilepsies, Partial, 3 studies
- Neuralgia, Postherpetic, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.